Dr. Reddy's Laboratories Limited (DRREDDY) — Financial Results | 23 January 2025

{ "summary": "Dr. Reddy's Laboratories reported consolidated revenue of ₹83.6 billion for Q3 FY25, up 16% YoY, driven by the Haleon NRT acquisition and strong European growth, with gross margin at 58.7%. Net profit stood at ₹14,133 million, reflecting integration costs and tax impacts. The company completed a 1:5 stock split effective October 28, 2024, and acquired Haleon's global NRT business for ₹55,897 million, adding ₹7,249 million in goodwill. Segment revenue from Global Generics rose 14% YoY, while Pharma Services grew 22%. R&D investment remained steady at 8.4% of revenue. The Board approved results on January 23, 2025, following a limited audit review with no material misstatements identified.", "extractedFields": { "keyEvent": "Dr. Reddy's Laboratories approved Q3 FY25 results and completed Haleon NRT acquisition.", "whatChanged": "Net profit declined 5% YoY to ₹14,133 million due to tax and forex impacts; SG&A expenses rose 19% YoY.", "forwardGuidance": "The company reaffirmed its full-year revenue growth outlook, targeting double-digit growth in emerging markets and continued margin expansion.", "investorTakeaway": "Shareholders gained from strategic NRT acquisition and stock split, but near-term profit pressure persists due to integration costs.", "revenueQuarter": 83586, "revenueNineMonths": 240475, "grossProfitQuarter": 49052, "grossProfitNineMonths": 143165, "netProfitQuarter": 14038, "netProfitNineMonths": 41373, "basicEPSQuarter": 16.96, "basicEPSSixMonths": 15.07, "basicEPSNineMonths": 48.75, "dilutedEPSQuarter": 16.94, "dilutedEPSSixMonths": 15.05, "dilutedEPSNineMonths": 48.68, "segmentRevenuePharmaServices": 10221, "segmentRevenueGlobalGenerics": 73753, "segmentRevenueOthers": 1614, "segmentRevenueTotal": 85588, "segmentProfitPharmaServices": 2353, "segmentProfitGlobalGenerics": 45219, "segmentProfitOthers": 1480, "segmentProfitTotal": 49052, "acquisitionHaleonConsideration": 55897, "acquisitionHaleonGoodwill": 7249, "acquisitionHaleonIntangibles": 54920, "acquisitionNestleInvestment": 7340, "acquisitionNestlePortfolioPurchase": 2231, "deferredTaxAssetWriteOff": 482, "stockSplitRatio": "1:5", "paidUpSharesAsOfDec312024": 834424050, "treasuryShares": 1302980, "grossMarginQ3FY25": 58.7, "grossMargin9MFY25": 59.5, "profitAfterTaxQ3FY25": 14133, "profitAfterTax9MFY25": 40606, "epsDiluted": 0.57, "stockSplitEffectiveDate": "28 October 2024", "haleonNRTBusinessAcquisition": true, "nutraceuticalPartnershipWithNestle": true, "deferredTaxAssetWriteOffAmount": 482, "totalRevenueQuarter": 50150, "totalRevenueNineMonths": 175525, "profitBeforeTaxQuarter": 11194, "profitBeforeTaxNineMonths": 56741, "basicEarningsPerShareQuarter": 10.20, "basicEarningsPerShareNineMonths": 22.60, "dilutedEarningsPerShareQuarter": 10.18, "dilutedEarningsPerShareNineMonths": 22.56, "segmentRevenuePharmaServicesAndActiveIngredientsQuarter": 10387, "segmentRevenuePharmaServicesAndActiveIngredientsNineMonths": 32049, "segmentRevenueGlobalGenericsQuarter": 73813, "segmentRevenueGlobalGenericsNineMonths": 214378, "segmentRevenueOthersQuarter": 1614, "segmentRevenueOthersNineMonths": 2005, "milestonePaymentReceived": 1266, "nonControllingInterest": 3844, "totalComprehensiveIncomeQuarter": 12018, "totalComprehensiveIncomeNineMonths": 42340, "earningsPerShareBasicQuarter": 16.97, "earningsPerShareBasicNineMonths": 48.77, "earningsPerShareDilutedQuarter": 16.94, "earningsPerShareDilutedNineMonths": 48.69, "paidUpEquityShareCapital": 834, "auditReportConclusion": "No material misstatement identified", "auditScope": "Limited review under SEBI Regulation 33", "auditFirm": "S.R. Batliboi & Associates LLP", "auditFirmRegistration": "101049W/E300004", "partnerName": "Shankar Ruv", "impairmentOfNonCurrentAssets": 907, "governmentGrantsAccounted": 84, "totalExpensesQ32024": 41310, "totalExpensesNineMonths2024": 125071, "netProfitQ32024": 8494, "netProfitNineMonths2024": 41487, "earningsPerShareBasicQ32024": 10.20, "earningsPerShareBasicNine